Glenmark Pharmaceuticals Statistics

Total Valuation

Glenmark Pharmaceuticals has a market cap or net worth of INR 435.04 billion. The enterprise value is 434.64 billion.

Market Cap	435.04B
Enterprise Value	434.64B

Important Dates

The next estimated earnings date is Friday, February 7, 2025.

Earnings Date	Feb 7, 2025
Ex-Dividend Date	Sep 13, 2024

Share Statistics

Glenmark Pharmaceuticals has 282.19 million shares outstanding. The number of shares has increased by 0.04% in one year.

Current Share Class	n/a
Shares Outstanding	282.19M
Shares Change (YoY)	+0.04%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	3.79%
Owned by Institutions (%)	34.45%
Float	139.19M

Valuation Ratios

PE Ratio	n/a
Forward PE	27.41
PS Ratio	3.33
PB Ratio	5.15
P/TBV Ratio	6.13
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.85, with an EV/FCF ratio of -20.92.

EV / Earnings	-49.66
EV / Sales	3.32
EV / EBITDA	19.85
EV / EBIT	24.40
EV / FCF	-20.92

Financial Position

The company has a current ratio of 1.46, with a Debt / Equity ratio of 0.21.

Current Ratio	1.46
Quick Ratio	0.76
Debt / Equity	0.21
Debt / EBITDA	0.81
Debt / FCF	-0.86
Interest Coverage	4.80

Financial Efficiency

Return on equity (ROE) is -10.93% and return on invested capital (ROIC) is 8.86%.

Return on Equity (ROE)	-10.93%
Return on Assets (ROA)	6.32%
Return on Capital (ROIC)	8.86%
Revenue Per Employee	8.73M
Profits Per Employee	-583,879
Employee Count	14,989
Asset Turnover	0.74
Inventory Turnover	1.59

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +87.20% in the last 52 weeks. The beta is 0.87, so Glenmark Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.87
52-Week Price Change	+87.20%
50-Day Moving Average	1,612.34
200-Day Moving Average	1,378.45
Relative Strength Index (RSI)	48.05
Average Volume (20 Days)	681,171

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Glenmark Pharmaceuticals had revenue of INR 130.80 billion and -8.75 billion in losses. Loss per share was -31.01.

Revenue	130.80B
Gross Profit	87.06B
Operating Income	17.82B
Pretax Income	9.44B
Net Income	-8.75B
EBITDA	20.94B
EBIT	17.82B
Loss Per Share	-31.01

Full Income Statement

Balance Sheet

The company has 18.20 billion in cash and 17.81 billion in debt, giving a net cash position of 393.95 million or 1.40 per share.

Cash & Cash Equivalents	18.20B
Total Debt	17.81B
Net Cash	393.95M
Net Cash Per Share	1.40
Equity (Book Value)	84.45B
Book Value Per Share	299.23
Working Capital	28.49B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -13.44 billion and capital expenditures -7.33 billion, giving a free cash flow of -20.77 billion.

Operating Cash Flow	-13.44B
Capital Expenditures	-7.33B
Free Cash Flow	-20.77B
FCF Per Share	-73.61

Full Cash Flow Statement

Margins

Gross margin is 66.56%, with operating and profit margins of 13.62% and -6.69%.

Gross Margin	66.56%
Operating Margin	13.62%
Pretax Margin	7.22%
Profit Margin	-6.69%
EBITDA Margin	16.01%
EBIT Margin	13.62%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 2.50, which amounts to a dividend yield of 0.16%.

Dividend Per Share	2.50
Dividend Yield	0.16%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.04%
Shareholder Yield	0.13%
Earnings Yield	-2.01%
FCF Yield	-4.77%

Dividend Details

Stock Splits

The last stock split was on September 10, 2007. It was a forward split with a ratio of 2.

Last Split Date	Sep 10, 2007
Split Type	Forward
Split Ratio	2

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a